Vorsitz/Chair: Harald Rittger (Fürth), Malte Tiburcy (Göttingen)
Agenda
09:45
(V417)
SGLT2 inhibitors and clinical outcomes in LVAD patients – a retrospective cohort study
J. Dr. Mulzer (Berlin)
Zum Abstract
09:52
Diskussion
09:56
(V418)
Impact of optimal medical therapy with SGLT2 inhibitor on left ventricular ejection fraction recovery in a pre vs post guideline era in HFrEF patients fitted with a wearable cardioverter defibrillator
V. Johnson (Frankfurt am Main)
Zum Abstract
10:03
Diskussion
10:07
(V419)
EVOLUTION HF - Early treatment of heart failure: a non-interventional study program of patients with heart failure and initiated on dapagliflozin: study design of German EVOLUTION HF DEallEF study
M. Paul (Steinfurt)
Zum Abstract
10:14
Diskussion
10:18
(V420)
Assessment of PVR and other hemodynamic parameters in HFpEF and HFmrEF patients with new-onset SGLT-2 inhibitor: Comparison of PAP sensor-derived and echo-based approaches
E. Herrmann (Gießen)
Zum Abstract
10:25
Diskussion
10:29
(V421)
Impact of the SGLT2 inhibitor on patients undergoing cardiac surgery
Z. Taghiyev (Gießen)
Zum Abstract
10:36
Diskussion
10:40
(V422)
Atherosclerotic cardiovascular disease as well as obesity without diabetes mellitus: Semaglutide as a new possibility in Germany
V. Oettinger (Freiburg)
Zum Abstract
10:47
Diskussion
10:51
(V423)
Impact of Diabetes on Cardiomyocyte Stiffness and Beta-Adrenergic Pathways in Heart Failure with Normal LVEF
H. Budde (Bochum)
Zum Abstract
10:58
Diskussion
11:02
(V424)
Loss of glyoxalase 1 protects heart from failure through induction of aldo-keto reductase